Decoding 5 Analyst Evaluations For Xencor
Portfolio Pulse from Benzinga Insights
Over the past three months, five analysts have shared their evaluations of Xencor (NASDAQ:XNCR), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has decreased by 11.7%, reflecting a negative shift in sentiment. Analysts from firms like JP Morgan, Raymond James, BMO Capital, RBC Capital, and Wedbush have adjusted their ratings and price targets, mostly lowering them. Xencor, a clinical-stage biopharmaceutical company, has faced a 32.47% decline in revenue growth and has below-average ROE and ROA, but maintains a low debt-to-equity ratio.
July 31, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Xencor has received mixed analyst ratings over the past three months, with a recent negative shift in sentiment as the average price target decreased by 11.7%. The company has faced a significant decline in revenue growth and has below-average ROE and ROA, but maintains a low debt-to-equity ratio.
The decrease in the average price target by 11.7% and the significant decline in revenue growth indicate a negative short-term outlook for Xencor. Despite strong debt management, the below-average ROE and ROA further contribute to the bearish sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100